NASDAQ:AGEN Agenus (AGEN) Stock Price, News & Analysis → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free AGEN Stock Alerts $10.86 +0.36 (+3.43%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$10.30▼$11.4150-Day Range$4.97▼$13.4752-Week Range$4.78▼$42.60Volume430,354 shsAverage Volume1.08 million shsMarket Capitalization$228.05 millionP/E RatioN/ADividend YieldN/APrice Target$70.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Agenus alerts: Email Address Agenus MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside544.6% Upside$70.00 Price TargetShort InterestBearish16.80% of Float Sold ShortDividend StrengthN/ASustainability-0.93Upright™ Environmental ScoreNews Sentiment0.84Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($9.70) to ($8.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.90 out of 5 starsMedical Sector202nd out of 918 stocksBiological Products, Except Diagnostic Industry23rd out of 152 stocks 3.5 Analyst's Opinion Consensus RatingAgenus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAgenus has only been the subject of 2 research reports in the past 90 days.Read more about Agenus' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.80% of the float of Agenus has been sold short.Short Interest Ratio / Days to CoverAgenus has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Agenus has recently increased by 25.10%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAgenus does not currently pay a dividend.Dividend GrowthAgenus does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAgenus has received a 72.61% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Agenus is -0.93. Previous Next 2.7 News and Social Media Coverage News SentimentAgenus has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Agenus this week, compared to 3 articles on an average week.Search InterestOnly 40 people have searched for AGEN on MarketBeat in the last 30 days. This is a decrease of -34% compared to the previous 30 days.MarketBeat FollowsOnly 18 people have added Agenus to their MarketBeat watchlist in the last 30 days. This is a decrease of -28% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Agenus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of Agenus is held by insiders.Percentage Held by Institutions61.46% of the stock of Agenus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Agenus' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Agenus are expected to grow in the coming year, from ($9.70) to ($8.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agenus is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agenus is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Agenus' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Agenus Stock (NASDAQ:AGEN)Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Read More AGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AGEN Stock News HeadlinesMay 16 at 8:52 AM | finance.yahoo.comFDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal CancerMay 15 at 9:15 AM | insidermonkey.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2024 Earnings Call TranscriptMay 15 at 1:32 AM | americanbankingnews.comAgenus Inc. (NASDAQ:AGEN) Short Interest Up 25.1% in AprilMay 13, 2024 | americanbankingnews.comAgenus Inc. Expected to Post Q2 2024 Earnings of ($0.02) Per Share (NASDAQ:AGEN)May 11, 2024 | americanbankingnews.comWilliam Blair Comments on Agenus Inc.'s Q2 2024 Earnings (NASDAQ:AGEN)May 11, 2024 | americanbankingnews.comQ2 2024 Earnings Estimate for Agenus Inc. Issued By HC Wainwright (NASDAQ:AGEN)May 10, 2024 | markets.businessinsider.comBuy Rating for Agenus Inc. on Strong Financial Position and Promising Clinical MilestonesMay 9, 2024 | seekingalpha.comAgenus GAAP EPS of -$3.04 beats by $0.18, revenue of $28M misses by $19.17MMay 8, 2024 | finance.yahoo.comAgenus Inc. (NASDAQ:AGEN) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comAgenus First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 8, 2024 | americanbankingnews.comAgenus (NASDAQ:AGEN) Receives Buy Rating from HC WainwrightMay 8, 2024 | finance.yahoo.comAgenus Inc (AGEN) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...May 7, 2024 | washingtonpost.comAgenus: Q1 Earnings SnapshotMay 7, 2024 | msn.comAGEN Stock Earnings: Agenus Misses EPS, Misses Revenue for Q1 2024May 7, 2024 | fool.comAgenus (AGEN) Q1 2024 Earnings Call TranscriptMay 7, 2024 | finance.yahoo.comAgenus Inc (AGEN) Q1 2024 Earnings: Misses Revenue and EPS Estimates Amid Strategic DevelopmentsMay 7, 2024 | businesswire.comAgenus Reports First Quarter 2024 ResultsMay 7, 2024 | businesswire.comLigand and Agenus Enter Into $100 Million Royalty Financing AgreementMay 1, 2024 | msn.comWhat to Make of Agenus Stock (NASDAQ:AGEN) Post Reverse Stock SplitMay 1, 2024 | finance.yahoo.comAgenus Regains Compliance with Nasdaq Minimum Bid Price RequirementApril 30, 2024 | seekingalpha.comTime Is Running Out For Agenus To Raise CashApril 29, 2024 | msn.comCompare with S&P 500 Growth Index SGD Total Return (500GST)April 28, 2024 | fool.comUp 40%: Is This Red-Hot Growth Stock Still a Buy?April 28, 2024 | fool.comUp 40%: Is This Red-Hot Growth Stock Still a Buy?April 27, 2024 | finance.yahoo.comAgenus Inc. (AGEN)See More Headlines Receive AGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today5/18/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:AGEN CUSIP00847G70 CIK1098972 Webagenusbio.com Phone(781) 674-4400Fax781-674-4200Employees389Year FoundedN/APrice Target and Rating Average Stock Price Target$70.00 High Stock Price Target$100.00 Low Stock Price Target$40.00 Potential Upside/Downside+544.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($12.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-245,760,000.00 Net Margins-154.88% Pretax Margin-154.88% Return on EquityN/A Return on Assets-77.55% Debt Debt-to-Equity RatioN/A Current Ratio0.24 Quick Ratio0.24 Sales & Book Value Annual Sales$156.31 million Price / Sales1.46 Cash FlowN/A Price / Cash FlowN/A Book Value($9.06) per share Price / Book-1.20Miscellaneous Outstanding Shares21,000,000Free Float19,991,000Market Cap$228.06 million OptionableOptionable Beta1.25 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Garo H. Armen Ph.D. (Age 71)Founder, Executive Chairman & CEO Comp: $1.34MMs. Christine M. Klaskin (Age 58)VP of Finance, Principal Financial Officer & Principal Accounting Officer Comp: $407.44kDr. Steven J. O'Day M.D. (Age 63)Ph.D., Chief Medical Officer Comp: $970.98kCraig WinterChief Information OfficerMr. Zack ArmenHead of Investor RelationsMs. Tracy Mazza ClementeChief People OfficerMr. Alfred DadsonChief Manufacturing OfficerMr. Eric HumesChief Quality OfficerDr. Todd Jude Yancey M.D.Member of Advisory Board & Chief Strategic AdvisorDr. Robin G. Taylor M.B.A.Ph.D., Chief Commercial OfficerMore ExecutivesKey CompetitorsOyster Point PharmaNASDAQ:OYSTSangamo TherapeuticsNASDAQ:SGMOCurisNASDAQ:CRISZura BioNASDAQ:ZURACompass TherapeuticsNASDAQ:CMPXView All CompetitorsInsiders & InstitutionsOracle Investment Management Inc.Sold 350,000 shares on 5/15/2024Ownership: 5.081%Price T Rowe Associates Inc. MDBought 123,058 shares on 5/15/2024Ownership: 1.704%American International Group Inc.Sold 1,613 shares on 5/14/2024Ownership: 0.894%Vanguard Group Inc.Bought 4,134,232 shares on 5/10/2024Ownership: 169.589%Acadian Asset Management LLCBought 720,629 shares on 5/10/2024Ownership: 3.734%View All Insider TransactionsView All Institutional Transactions AGEN Stock Analysis - Frequently Asked Questions Should I buy or sell Agenus stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AGEN shares. View AGEN analyst ratings or view top-rated stocks. What is Agenus' stock price target for 2024? 3 analysts have issued 1-year target prices for Agenus' stock. Their AGEN share price targets range from $40.00 to $100.00. On average, they anticipate the company's share price to reach $70.00 in the next twelve months. This suggests a possible upside of 544.6% from the stock's current price. View analysts price targets for AGEN or view top-rated stocks among Wall Street analysts. How have AGEN shares performed in 2024? Agenus' stock was trading at $16.5580 on January 1st, 2024. Since then, AGEN shares have decreased by 34.4% and is now trading at $10.86. View the best growth stocks for 2024 here. When is Agenus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our AGEN earnings forecast. How were Agenus' earnings last quarter? Agenus Inc. (NASDAQ:AGEN) released its quarterly earnings data on Thursday, March, 14th. The biotechnology company reported ($2.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $2.20. The biotechnology company earned $83.80 million during the quarter, compared to analyst estimates of $54.21 million. What ETFs hold Agenus' stock? ETFs with the largest weight of Agenus (NASDAQ:AGEN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA). When did Agenus' stock split? Shares of Agenus reverse split on the morning of Friday, April 12th 2024. The 1-20 reverse split was announced on Friday, April 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Garo H. Armen's approval rating as Agenus' CEO? 2 employees have rated Agenus Chief Executive Officer Garo H. Armen on Glassdoor.com. Garo H. Armen has an approval rating of 56% among the company's employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Agenus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agenus investors own include (ROSG) (ROSG), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), OPKO Health (OPK), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Gilead Sciences (GILD), Matinas BioPharma (MTNB) and RedHill Biopharma (RDHL). Who are Agenus' major shareholders? Agenus' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (169.59%), GSA Capital Partners LLP (6.27%), Oracle Investment Management Inc. (5.08%), Key Client Fiduciary Advisors LLC (4.10%), Acadian Asset Management LLC (3.73%) and Hennion & Walsh Asset Management Inc. (2.67%). Insiders that own company stock include Agenus Inc, Christine M Klaskin, Garo H Armen and Steven J O'day. View institutional ownership trends. How do I buy shares of Agenus? Shares of AGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AGEN) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaObama’s Forever Term [exposed]Porter & CompanyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryMost important medical advance in 100 yearsThe Oxford ClubBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
